A new stem cell method for culturing hairfollicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
A Swiss product called Redensyl, which is supposed to target hairfollicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
MCL-1 is important for hairfollicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.
HairClone is developing cell replacement treatments to rejuvenate and generate hairfollicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
A dermatologist advised using only minoxidil for hair loss, citing it as a lifelong therapy and dismissing finasteride due to potential side effects. Several users disagreed, recommending a combination of minoxidil and finasteride for better results.